HPV相关口咽鳞癌患者拒绝术后放疗的因素与生存关联
基于美国国家癌症数据库2010至2015年确诊的HPV相关口咽鳞癌患者,共4229例纳入分析,其中156例(3.7%)拒绝推荐的术后放疗。
要点
- HPV相关口咽鳞癌中拒绝术后放疗少见,本队列为3.7%。
- 拒绝术后放疗与多种社会经济及疾病因素独立相关。
核心结论
- 在HPV相关口咽鳞癌患者中,拒绝推荐的术后放疗虽少见,但与总生存降低相关,可辅助临床咨询与识别高危拒绝人群。
研究设计与样本
- 最终分析共纳入4229例患者,其中156例(3.7%)拒绝推荐的术后放疗。
- 采用多因素logistic回归和多因素Cox比例风险模型分析。
主要发现
- 多因素分析中,拒绝术后放疗与种族、保险状态、合并症、单一机构治疗及切缘状态等社会经济因素独立相关。
关键数值与推荐
- 拒绝术后放疗患者156例,占全部4229例的3.7%。
- 证据等级为3。
临床怎么用
- 临床可据此在咨询中识别更可能拒绝术后放疗的HPV相关口咽鳞癌患者,并加强辅助治疗沟通。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES/HYPOTHESIS: Human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC) is a distinct clinical entity with good prognosis, unique demographics, and a trend toward treatment deintensification. Patients with this disease may opt out of recommended postoperative radiation therapy (PORT) for a variety of reasons. The aim of this paper was to examine factors that predict patient refusal of recommended PORT in HPV-associated OPSCC, and the association of refusal with overall survival. STUDY DESIGN: Retrospective population-based cohort study of patients in the National Cancer Database. METHODS: We conducted a retrospective cohort study of patients in the National Cancer Database diagnosed with OPSCC between January 2010 and December 2015. We primarily assessed overall survival and the odds of refusing PORT based on demographic, socioeconomic, and clinical factors. Analysis was conducted using multivariable logistic regression and multivariable Cox proportional hazards model. RESULTS: A total of 4229 patients were included in the final analysis, with 156 (3.7%) patients opting out of recommended PORT. On multivariable analysis, patient refusal of PORT was independently associated with a variety of socioeconomic factors such as race, insurance status, comorbidity, treatment at a single facility, and margin status. Lastly, PORT refusal was associated with significantly lower overall survival compared to receipt of recommended PORT (hazard ratio 1.69, confidence interval 1.02-2.82). CONCLUSIONS: Patient refusal of recommended PORT in HPV-associated OPSCC is rare and associated with variety of disease and socioeconomic factors. PORT refusal may decrease overall survival in this population. Our findings may help clinicians when counseling patients and identifying those who may be more likely to opt out of recommended adjuvant therapy. LEVEL OF EVIDENCE: 3 Laryngoscope, 132:339-348, 2022.
引用
- Prasad A, Carey RM, Brody RM, et al. Postoperative Radiation Therapy Refusal in Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma. Laryngoscope. 2021. PMID: 34254672. doi:10.1002/lary.29743
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。